Perrigo's (PRGO) Generic Epiduo Gel Garners Tentative FDA Approval
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Perrigo Company plc (NYSE: PRGO) announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Epiduo Gel (adapalene and benzoyl peroxide 0.1%/2.5%).
Epiduo® Gel (adapalene and benzoyl peroxide 0.1%/2.5%) is indicated for the treatment of acne vulgaris in patients 12 years of age and older. Annual sales for the 12 months ending July 2016 were $379 million.
Perrigo's CEO John T. Hendrickson stated, "This tentative approval is another example of Perrigo's ongoing commitment to developing high quality value alternatives in important treatment categories. The Rx team continues to leverage Perrigo's development capabilities in order to deliver Quality Affordable Healthcare Products® to our customers and consumers around the world."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Windtree Therapeutics (WINT) Releases Data from Lung Deposition Study Conducted in Non-Human Primates
- Finjan Holdings (FNJN) Receives European Patent Related to Adaptive Rule-Based Content Scanners
- Global Blood Therapeutics (GBT) Reaches Agreement with FDA on Design of Phase 3 GBT440 Trial in SCD
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!